Compared with PARP inhibitor or Cisplatin, SOSTDC1 knockdown did not impact cell sensibility to Docetaxel (DTX), which stops the growth of cancer cells by interfering with microtubules and blocking cell division (Figure S7B, Supporting Information). The gene discussed is SOSTDC1; the disease is cancer.